Antibodies against the RGM a protein and uses thereof

US9605069B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Bernhard Mueller · Neustadt, DE
• Martin Schmidt · Frankfurt am Main, DE
• Eve H. Barlow · Princeton, US
• Mary Leddy · North Attleborough, US
• Chung-Ming Hsieh · Newton, US
• Philip Bardwell · Boston, US

Key dates

• Filing date: Jan 7, 2015
• Grant date: Mar 28, 2017
• Expiry date: Jan 29, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.